Merck obtains rights to experimental Ebola vaccine

November 24, 2014 4:23 PM

5 0

Merck obtains rights to experimental Ebola vaccine

Merck & Co. has obtained the rights to an experimental Ebola vaccine developed by NewLink Genetics Corp., another sign of the scramble by pharmaceutical companies and other groups to find new ways to combat the deadly viral outbreak centered in West Africa.

The companies said Merck will pay NewLink $30 million upfront, plus an additional $20 million when new clinical trials to test the vaccine’s efficacy get under way, which is expected by the first quarter of 2015. Merck MRK, -0.69% also will pay royalties to NewLink NLNK, -2.52% on sales of the p...

Also read: Irish Court Orders Russian Oligarch's Assets Unfrozen

Read more

To category page

Loading...